绝经后激素受体阳性晚期乳腺癌的内分泌治疗

doi:10.3760/cma.j.issn.1673422X.2016.07.012

摘要/Abstract

摘要： 随着内分泌新药的出现及对内分泌治疗耐药机制研究的不断发展，乳腺癌内分泌治疗近年取得显著进步。氟维司群、内分泌药物之间的联合治疗以及内分泌联合靶向治疗成为治疗绝经后激素受体阳性晚期乳腺癌的有效方案。

Abstract: With the emergence of new endocrine drugs and the development of research in resistance mechanisms, significant progress has been achieved in the endocrine treatment of breast cancer in recent years. Fulvestrant, the combination of endocrine drugs and the combination of targeted therapy with endocrine therapy will be effective treatments for postmenopausal women with hormone receptor positive in advanced breast cancer.

Key words: Breast neoplasms, Receptors, estrogen, Therapy

黄雪香, 石磊. 绝经后激素受体阳性晚期乳腺癌的内分泌治疗[J]. 国际肿瘤学杂志, 2016, 43(7): 529-531.

HUANG Xue-Xiang, SHI Lei. Endocrine therapy for postmenopausal women with hormone receptor positive in advanced breast cancer[J]. Journal of International Oncology, 2016, 43(7): 529-531.

参考文献

［1］ Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, doubleblind, randomized trial［J］. J Clin Oncol, 2004, 22(9): 16051613. DOI: 10.1200/JCO.2004.02.112. ［2］ Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer［J］. J Clin Oncol, 2010, 28(30): 45944600. DOI: 10.1200/JCO.2010.28.8415. ［3］ Di Leo A, Jerusalem G, Petruzelka L, et al. Final analysis of overall survival for the phase Ⅲ CONFIRM trial: fulvestrant 500 mg versus 250 mg［J］. Cancer Res, 2012, 72(24a): 2167. ［4］ Robertson JF, LlombartCussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as firstline treatment for advanced breast cancer: results from the FIRST study［J］. J Clin Oncol, 2009, 27(27): 45304535. DOI: 10.1200/JCO.2008.21.1136. ［5］ Robertson JF, Lindemann JP, LlombartCussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the firstline treatment of advanced breast cancer: followup analysis from the randomized first study［J］. Breast Cancer Res Treat, 2012, 136(2): 503511. DOI: 10.1007/s1054901221924. ［6］ Ellis MJ, LombartCussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole as firstline treatment for advanced breast cancer overall survival from the phase Ⅱ first study［J］. J Clin Oncol, 2015, 33(32): 37813787. DOI: 10.1200/JCO.2015.61.5831. ［7］ Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer［J］. N Engl J Med, 2012, 367(5): 435444. DOI: 10.1056/NEJMoa1201622. ［8］ Bergh J, Jnsson PE, Lidbrink EK, et al. FACT: an openlabel randomized phase Ⅲ study of fulvestrant and anastrozole in combination compared with anastrozole alone as firstline therapy for patients with receptorpositive postmenopausal breast cancer［J］. J Clin Oncol, 2012, 30(16): 19191925. DOI: 10.1200/JCO.2011.38.1095. ［9］ Johnston S, Kilburn LS, Ellis P, et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on nonsteroidal aromatase inhibitorfirst results of the SoFEa trial［J］. Eur J Cancer, 2012, 48(3): S2. ［10］ Traina TA, Rugo HS, Caravelli JF, et a1. Feasibility al of letrozole in combination with bevacizumab in patients with metastatic breast cancer［J］. J Clin Oncol, 2010, 28: 628633. DOI: 10.1200/JCO.2009.21.8784. ［11］ Martín M, Loibl S, Von Minckwitz G, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as firstline treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study［J］. J Clin Oncol, 2015, 33(9): 10451052. DOI: 10.1200/JCO.2014.57.2388. ［12］ Bachelot T, Bourgier C, Cropet C, et al. Randomized phase Ⅱ trial of everolimus in combination with tamoxifen versus tamoxifen alone in patient with hormone receptorpositive, human epidermal growth factor receptor 2negative metastatic breast cancer with prior exposure to aromatase inhibitors(AI): a GINECO study［J］. J Clin Oncol, 2012, 30(22): 27182724. DOI: 10.1200/JCO.2011.39.0708. ［13］ Piccart M, Baselga J, Noguchi S, et al. Final progressionfree survival analysis of BOLERO2: a phase Ⅲ trial of everolimus for postmenopausal women with advanced breast cancer［J］. Cancer Res, 2012, 72(24a): 1743. DOI: 10.1007/s1232501300601. ［14］ Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase Ⅲ placebocontrolledtrial of letrozole plus oral temsirolimus as firstline endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer［J］. J Clin Oncol, 2013, 31(2): 195202. DOI: 10.1200/JCO.2011.38.3331. ［15］ Finn RS, Crown JP, Lang I, et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as firstline treatment of oestrogen receptorpositive, HER2negative, advanced breast cancer (PALOMA1/TRIO18): a randomised phase 2 study［J］. Lancet Oncol, 2015, 16(1): 2535. DOI: 10.1016/S14702045(14)711593.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[15]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.